SYT 510
Alternative Names: SYT-510Latest Information Update: 22 Jan 2024
At a glance
- Originator NCCR TransCure; University of Bern
- Developer University of Bern
- Class Anxiolytics; Mood stabilisers; Small molecules
- Mechanism of Action Anandamide reuptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Mood disorders; Traumatic stress disorders
Most Recent Events
- 18 Jan 2024 European Medicine Agency approves clinical trial application for phase I trial of SYT 510 in Neuropsychiatric disorders
- 18 Jan 2024 Synendos plans phase I trials in Neuropsychiatric disorders (In Volunteers) in 2023 (Synendos Therapeutics pipeline, October 2023)
- 26 Oct 2021 Synendos Therapeutics announces intention to submit IND application and Clinical Trial Application for Neuropsychiatric disorders